Truist Financial’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-583
Closed -$156K 2701
2021
Q4
$156K Sell
583
-2
-0.3% -$525 ﹤0.01% 2635
2021
Q3
$171K Sell
585
-5
-0.8% -$1.46K ﹤0.01% 2595
2021
Q2
$146K Sell
590
-1
-0.2% -$257 ﹤0.01% 2631
2021
Q1
$169K Buy
+591
New +$236K ﹤0.01% 2530

Other funds holding CODX

Truist Financial's CODX Position: Q1 2022 in Review

Truist Financial sold out of Co-Diagnostics (CODX) in Q1 2022, closing a stake of 583 shares — an estimated $156K sold.

Truist Financial first reported a position in CODX in Q1 2021 and held it in 4 quarters. The position peaked at $171K in Q3 2021. 82 funds tracked by Wall St. Rank hold CODX as of Q1 2022.

  • Truist Financial reported no remaining Co-Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Truist Financial sold 583 Co-Diagnostics shares in Q1 2022, an estimated $156K.
  • Truist Financial first reported a position in Co-Diagnostics in Q1 2021 and held it in 4 quarters.
  • Truist Financial's Co-Diagnostics position peaked at $171K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.